Drug Profile
YK FH312
Alternative Names: YK-FH312Latest Information Update: 12 Jan 2004
Price :
$50
*
At a glance
- Originator Kagoshima University Dental School; Niigata University of Pharmacy and Applied Life Sciences; Osaka Medical College
- Class Antivirals
- Mechanism of Action Nucleocapsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 12 Jan 2004 No development reported - Preclinical for HIV-1 infections in Japan (unspecified route)
- 25 Sep 2001 Preclinical development for HIV-1 infections in Japan (Unknown route)